BN Business News
أضف شركتك →
تجري حاليًا ترجمة هذا المقال. نعرض مؤقتًا النسخة الأصلية باللغة الإنجليزية.

الأعمال · 31‏/5‏/20181 دقائق للقراءة

Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management; International Council for Harmonisation; Draft Guidance for Industry; Availability

ترجمة آلية محلية · اللغة الأصلية للمصدر

الملخص

The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance entitled "Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management; International Council for Harmonisation." The draft guidance was prepared under the auspices of the International Council for Harmonisation (ICH), formerly the International Conference on Harmonisation. The draft guidance, which consists of a Core Guideline and an Annex, provides a framework to facilitate the management of post-approval chemistry, manufacturing, and controls changes for new and marketed pharmaceutical drug substances and drug products, including marketed chemical and biotechnological/biological products.

اللغة الأصلية للمصدر: Federal Register — Food and Drug Administrationافتح البيان الأصلي →

استكشف الموضوعات

تحليلات الأعمال →